001026459 001__ 1026459
001026459 005__ 20250203103352.0
001026459 037__ $$aFZJ-2024-03408
001026459 041__ $$aEnglish
001026459 1001_ $$0P:(DE-Juel1)180770$$aHoffmann, Chris$$b0$$eCorresponding author
001026459 1112_ $$a25th International Symposium on Radiopharmaceutical Sciences$$cHonolulu, USA$$d2023-05-22 - 2023-05-26$$gISRS2023$$wUSA
001026459 245__ $$aPreparation of radiolabeled sulfamoyl fluorides by SuFEx 18F/19F isotopic exchange and assessment of their in vivo stability
001026459 260__ $$c2023
001026459 3367_ $$033$$2EndNote$$aConference Paper
001026459 3367_ $$2DataCite$$aOther
001026459 3367_ $$2BibTeX$$aINPROCEEDINGS
001026459 3367_ $$2DRIVER$$aconferenceObject
001026459 3367_ $$2ORCID$$aLECTURE_SPEECH
001026459 3367_ $$0PUB:(DE-HGF)6$$2PUB:(DE-HGF)$$aConference Presentation$$bconf$$mconf$$s1716544325_30286$$xAfter Call
001026459 520__ $$aObjectives: Aryl fluorosulfates (FO 2 S-O-) and disubstituted sulfa-moyl fluorides (FO 2S-N-) often possess high hydrolytic stability and arewidely used in chemical biology and drug design. Recently we reporteda protocol for convenient preparation of radiolabeled aryl fluorosul-fates with high molar activity via fast 18 F/19 F isotopic exchange [1]. Theaim of the present work was to study the suitability of this procedurefor radiofluorination of sulfamoyl fluorides. To this end, the procedurewas applied to N-sulfamoylated indole and carbazole as well as tothree protected amino acids (Boc-Trp(SO2 F)-OMe 1, Boc-His(SO2F)-OMe 2 and Boc-2,3-DH-Trp(SO2 F)-OMe 3). Additionally, the in vivostability of the radiolabeled tryptophan derivative Boc-Trp([18 F]SO2F)-OMe ([18 F]1) was evaluated.Methods: Aqueous [18 F]fluoride was loaded onto an anionexchange QMA cartridge and eluted with Et 4NOH (10 μmol) inMeOH (1 mL). MeOH was evaporated, a solution of the correspondingsubstrate (31–125 nmol) in MeCN (500 μL) was added and the reactionmixture was stirred for 7 min at 40 °C. Thereafter, H2 O (1 mL) wasadded and radiochemical conversions (RCCs) were determined byradio-HPLC. [ 18 F]1 was isolated by solid phase extraction using aStrataX C18 cartridge. The tracer was formulated in Tween® 20 (200 μL)and 1 mm sodium phosphate buffer (2 μL; pH 7.2) and subjected to apreclinical evaluation in healthy mice using μPET.Results: Radiolabeled N–sulfamoyl fluorides of carbazole andindole were prepared in RCCs of 72 ± 2% and 86 ± 2%, respectively.FO 2SN-functionalized protected tryptophan 1 (RCC: 68 ± 5%), histidine2 (RCC: 3 ± 1%) and 2,3-dihydroxy-tryptophan 3 (RCC: 34%; 60°C,14 min), were also successfully radiofluorinated. Boc-Trp([18 F]SO2F)-OMe [18 F]1 was isolated in activity yields of 24 ± 2% with aradiochemical purity of 99% (n = 3) within 70 min using 12.5 μg (31 nmol) of precursor. In μPET experiments, the radiolabeled productshowed very low radioactivity accumulation in bones, indicating a lackof significant in vivo defluorination. The study also demonstratedalmost exclusive hepatobiliary elimination of the tracer, presumablyowing to its very high lipophilicity.Conclusions: The SuFEx protocol developed for radiolabeling offluorosulfates was successfully applied for the simple and fastpreparation of 18 F-labeled sulfamoyl fluorides. High metabolic stabilityof Boc-Trp(SO2 [ 18F]F)-OMe underlines the suitability of this class ofradiolabeled compounds as PET-probes for in vivo imaging.Reference[1] Walter N., Bertram J., Drewes B., Bahutski V., Timmer M., SchützM. B., Krämer F., Neumaier F., Endepols H., Neumaier B.,Zlatopolskiy B. D., European Journal of Medicinal Chemistry2022, 237, 114383.
001026459 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001026459 7001_ $$0P:(DE-Juel1)191040$$aBertram, Jan$$b1
001026459 7001_ $$0P:(DE-Juel1)180330$$aEndepols, Heike$$b2
001026459 7001_ $$0P:(DE-Juel1)185610$$aZlatopolskiy, Boris$$b3
001026459 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, Bernd$$b4$$eCorresponding author
001026459 8564_ $$uhttps://juser.fz-juelich.de/record/1026459/files/1-s2.0-S0969805123002068-main.pdf$$yRestricted
001026459 8564_ $$uhttps://juser.fz-juelich.de/record/1026459/files/1-s2.0-S0969805123002068-main.gif?subformat=icon$$xicon$$yRestricted
001026459 8564_ $$uhttps://juser.fz-juelich.de/record/1026459/files/1-s2.0-S0969805123002068-main.jpg?subformat=icon-1440$$xicon-1440$$yRestricted
001026459 8564_ $$uhttps://juser.fz-juelich.de/record/1026459/files/1-s2.0-S0969805123002068-main.jpg?subformat=icon-180$$xicon-180$$yRestricted
001026459 8564_ $$uhttps://juser.fz-juelich.de/record/1026459/files/1-s2.0-S0969805123002068-main.jpg?subformat=icon-640$$xicon-640$$yRestricted
001026459 909CO $$ooai:juser.fz-juelich.de:1026459$$pVDB
001026459 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)180770$$aForschungszentrum Jülich$$b0$$kFZJ
001026459 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)191040$$aForschungszentrum Jülich$$b1$$kFZJ
001026459 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)180330$$aForschungszentrum Jülich$$b2$$kFZJ
001026459 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)185610$$aForschungszentrum Jülich$$b3$$kFZJ
001026459 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b4$$kFZJ
001026459 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001026459 9141_ $$y2024
001026459 920__ $$lyes
001026459 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x0
001026459 980__ $$aconf
001026459 980__ $$aVDB
001026459 980__ $$aI:(DE-Juel1)INM-5-20090406
001026459 980__ $$aUNRESTRICTED